Topokine Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:2
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (66.7%)Phase 1
2 (33.3%)Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
Phase 1
Completed
- Conditions
- Nasolabial FoldsLipoatrophyLipodystrophy
- Interventions
- Drug: TAT4 Gel concentration ADrug: TAT4 Gel concentration BDrug: Placebo
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02647853
- Locations
- 🇺🇸
Topokine Clinical Site, Cypress, California, United States
Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale
Completed
- Conditions
- Steatoblepharon
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02609763
Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds
Phase 2
- Conditions
- Nasolabial Folds
- Interventions
- Drug: TAT4 GelDrug: Matching placebo
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT02607670
- Locations
- 🇺🇸
Topokine Research Site, Boston, Massachusetts, United States
Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)
Phase 2
Completed
- Conditions
- Steatoblepharon
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02607683
- Locations
- 🇺🇸
David Wirta, MD, Inc., Newport Beach, California, United States
🇺🇸OC Clinical Trials, Santa Ana, California, United States
🇺🇸Danbury Eye Physicians, Danbury, Connecticut, United States
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Phase 2
Completed
- Conditions
- Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
- Interventions
- Drug: PlaceboDrug: XOPH5 Ointment
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT02230761
- Locations
- 🇺🇸
Topokine Therapeutics Clinical Study Centers, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
No news found